Hostname: page-component-7b7567c8c-kwt9d Total loading time: 0 Render date: 2026-11-15T01:51:00.373Z Has data issue: false hasContentIssue false

Treatment options in moderate and severe depression: decisionanalysis supporting a clinical guideline

Published online by Cambridge University Press:  02 January 2018

Judit Simon*
Affiliation:
Health Economics Research Centre, Department of Public Health, University of Oxford and National Collaborating Centre for Mental Health (NCCMH), Centre for Outcomes, Research and Effectiveness, Sub-department of Clinical Psychology, University College London
Stephen Pilling
Affiliation:
Centre for Outcomes, Research and Effectiveness, Sub-department of Clinical Psychology, University College London and Camden and Islington Mental Health and Social Care Trust, London
Rachel Burbeck
Affiliation:
Royal College of Psychiatrists' Research Unit, London
David Goldberg
Affiliation:
Institute of Psychiatry, King's College, London, UK
*
Dr Judit Simon, Health Economics Research Centre, Old RoadCampus, Headington, Oxford OX3 7LF, UK. Tel: +44(0) 1865 226692; fax: +44(0)1865 226842; email: judit.simon@dphpc.ox.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Background

Treatment options for depression include antidepressants, psychological therapy and a combination of the two.

Aims

To develop cost-effective clinical guidelines.

Method

Systematic literature reviews were used to identify clinical, utility and cost data. A decision analysis was then conducted to compare the benefits and costs of antidepressants with combination therapy for moderate and severe depression in secondary care in the UK.

Results

Over the 15-month analysis period, combination therapy resulted in higher costs and an expected 0.16 increase per person in the probability of remission and no relapse compared with antidepressants. The cost per additional successfully treated patient was £4056 (95% CI 1400–18 300); the cost per quality-adjusted life year gained was £5777 (95% CI 1900–33 800) for severe depression and £14 540 (95% CI 4800–79 400) for moderate depression.

Conclusions

Combination therapy is likely to be a cost-effective first-line secondary care treatment for severe depression. Its cost-effectiveness for moderate depression is more uncertain from current evidence. Targeted combination therapy could improve resource utilisation.

Information

Type
Papers
Copyright
Copyright © Royal College of Psychiatrists, 2006 
Figure 0

Fig. 1Decision analysis structure and event probabilities (estimated from the clinical effectiveness parameters listed in Table 1).

Figure 1

Table 1Decision analysis parameters

Figure 2

Table 2Expected costs, effects and cost-effectiveness results over 15 months

Figure 3

Table 3Univariate sensitivity analysis

Figure 4

Fig. 2Risk difference (RD) between combination therapy and pharmacotherapy for moderate and severe depression: patients not completing 3-month treatment.

Figure 5

Fig. 3Risk difference (RD) between combination therapy and pharmacotherapy for moderate and severe depression: patients not achieving remission during treatment.

Figure 6

Fig. 4Risk difference (RD) between combination therapy and pharmacotherapy for moderate and severe depression: relapse over 12-month follow-up.

Figure 7

Fig. 5Cost-effectiveness acceptability curves: probability that combination therapy is cost-effective as a function of decision-makers’ willingness to pay per additional unit of health gain. QALY, quality-adjusted life-year.

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.